This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

The Cooper Companies Announces Third Quarter 2013 Results

PLEASANTON, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal third quarter ended July 31, 2013.

  • Revenue increased 9% year-over-year to $412.0 million. CooperVision (CVI) revenue up 5% to $330.5 million, up 9% in constant currency, and CooperSurgical (CSI) revenue up 27% to $81.5 million.  
  • GAAP earnings per share (EPS) $1.79, up 43 cents or 32% from last year's third quarter.  
  • Non-GAAP EPS $1.74, up 29 cents or 20% from last year's third quarter. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.  
  • Third quarter free cash flow $64.5 million.

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "I am pleased to report another strong quarter for the Company. We continued to gain market share within CVI, CSI posted solid revenue growth driven by fertility, and we generated strong EPS and significant free cash flow. We remain encouraged by our business trends and believe we are well positioned to deliver strong operating results to finish our fiscal year."

Third Quarter GAAP Operating Highlights

  • Revenue $412.0 million, up 9% from last year's third quarter, 12% in constant currency.  
  • Gross margin 65% compared with 63% in last year's third quarter. The increase was primarily the result of a lower royalty payment on silicone hydrogel lens sales, product mix and increased manufacturing efficiencies, partially offset by lower revenue due to currency, primarily the Yen.  
  • Operating margin 23% compared with 20% in last year's third quarter. The increase was the result of higher gross margins.  
  • Depreciation $23.4 million, up 7% from last year's third quarter. Amortization $7.7 million, up 31% from last year's third quarter, primarily related to intangible assets from the acquisition of Origio in July 2012.  
  • Total debt decreased $76.9 million in the quarter to $243.6 million. Interest expense $2.3 million down 2% from last year's third quarter.  
  • Cash provided by operations $103.1 million and capital expenditures $38.6 million resulted in free cash flow $64.5 million.

Third Quarter CooperVision GAAP Operating Highlights

  • Revenue $330.5 million, up 5% from last year's third quarter, 9% in constant currency.  
  • Revenue by category:
        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  3Q13 3Q13 y/y y/y
Toric  $ 101.5 31% 7% 8%
Multifocal  33.1 10% 33% 32%
Single-use sphere  70.7 21% -1% 9%
Non single-use sphere, other  125.2 38% 2% 4%
Total  $ 330.5 100% 5% 9%
  • Revenue by geography:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   3Q13  3Q13 y/y y/y
Americas  $ 143.0 43% 9% 9%
EMEA  118.4 36% 11% 8%
Asia Pacific  69.1 21% -9% 8%
Total  $ 330.5 100% 5% 9%
  • Selected revenue by material:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   3Q13  3Q13 y/y y/y
         
Silicone hydrogel  $ 143.0 43% 21% 22%
Proclear ®  $ 86.0 26% 9% 11%
  • Gross margin 65% compared with 63% in last year's third quarter. The increase was primarily the result of a lower royalty payment on silicone hydrogel lens sales, product mix and increased manufacturing efficiencies, partially offset by lower revenue due to currency, primarily the Yen.

Third Quarter CooperSurgical GAAP Operating Highlights

  • Revenue $81.5 million, up 27% from last year's third quarter, driven by the acquisition of Origio in July 2012.  
  • Revenue by category:
  (In millions) % of CSI Revenue %chg
  3Q13 3Q13 y/y
Office and surgical procedures  $ 54.0 66% 0%
Fertility  27.5 34% 180%
Total  $ 81.5 100% 27%
  • Gross margin 64% compared with 67% in last year's third quarter. The decrease was primarily the result of lower margins associated with the acquisition of Origio.

2013 Guidance

The Company revises its full year fiscal 2013 guidance. Guidance is summarized as follows:

  FY13 Guidance FY13 Guidance 4Q13 Guidance
  Old New New
Revenues (In millions)      
Total $1,575 - $1,605 $1,586 - $1,601 $410 - $425
CVI $1,260 - $1,280 $1,271 - $1,281 $330 - $340
CSI $315 - $325 $315 - $320 $80 - $85
EPS      
GAAP $6.42 - $6.52 $6.57 - $6.62 $1.76 - $1.81
Non-GAAP $6.15 - $6.25 $6.23 - $6.28 $1.76 - $1.81
Free Cash Flow (In millions) $170 - $200 $180 - $210 $19 - $49

Guidance assumes constant currency at the date of issuance and excludes the financial impact for the proposed sale of Aime announced on May 31, 2013.

Stock quotes in this article: COO 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs